Table 5.

Odds ratios^* and 95% confidence intervals for the association between uterine leiomyoma, overall and by race, for all ovarian cancer and stratified by histotype

	Overall	High-Grade Serous	Low-Grade Serous	Endometrioid	Clear Cell	Mucinous	p-het	Low-Grade Serous, Endo, & Clear Cell
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	(between histotypes)	OR (95% CI)
All participants (cases/controls)	2954/4917	1814/4917	101/4917	242/4917	195/4917	163/4917		538/4917
No	1.00	1.00	1.00	1.00	1.00	1.00		1.00
Yes	1.26 (1.12–1.41)	1.25 (1.09–1.43)	0.99 (0.59–1.64)	1.59 (1.18–2.15)	1.26 (0.89–1.78)	1.54 (1.07–2.23)	0.03	1.35 (1.09–1.68)
Black participants (cases/controls)	962/2033	614/2033	30/2033	82/2033	34/2033	48/2033		146/2033
No	1.00	1.00	1.00	1.00	1.00	1.00		1.00
Yes	1.34 (1.11–1.62)	1.32 (1.06–1.64)	2.05 (0.83–5.07)	2.05 (1.24–3.39)	1.64 (0.77–3.48)	1.92 (0.99–3.69)	0.002	1.92 (1.31–2.80)
White participants (cases/controls)	1992/2884	1200/2884	71/2884	160/2884	161/2884	115/2884		392/2884
No	1.00	1.00	1.00	1.00	1.00	1.00		1.00
Yes	1.22 (1.05–1.41)	1.18 (0.99–1.41)	0.77 (0.39–1.53)	1.41 (0.95–2.10)	1.27 (0.84–1.90)	1.45 (0.91–2.32)	0.33	1.21 (0.92–1.59)
pheterogeneity by race	0.54	0.69	0.22	0.21	0.39	0.52

^*Odd ratios were adjusted for site, age at diagnosis, education, parity, oral contraceptive duration, BMI, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, post-menopausal hormone duration, age at menarche, and premenopausal hysterectomy.